Genprex, Inc. announced that research collaborators will present positive clinical and preclinical data from studies of its lead product candidate, REQORSA®? (quaratusugene ozeplasmid) used for the treatment of lung cancer, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place from October 11-15, 2023 at the Hynes Convention Center in Boston. Dr. Spira's presentation will focus on the results of the Phase 1 dose escalation portion of the Acclaim-1 clinical trial of REQORSA in combination with Tagrisso®?

(osimertinib) to treat late-stage NSCLC. This was the dose level delivered in the Phase 1 portion and is twice the dose level delivered in Genprex's prior clinical trial combining REQORSA with Tarceva®? (erlotinib) for the treatment of late-stage NSCLC; The combination of REQORSA and Tagrisso received U.S. Food and Drug Administration's (FDA) Fast Track Designation for treatment of the Acclaim-1 patient population.

Genprex currently has three clinical trials evaluating the Company's lead drug candidate, REQORSA (quaratusugene Ozeplasmid) in lung cancer. The Acclaim-1 clinical trial, whose patient population received FDA Fast Track Designation, is an open-label, multi-center Phase 1/2 clinical trial evaluating REQORSA in combination With Tagrisso®? (OSimertinib) in patients with late-stage NSCLC with activating epidermal growth factor receptor mutations whose disease progressed after treatment with Tagrisso.

The Acclaim-2 clinical trial, whose patient population receive FDA Fast Track Designation, are an open-label, multi thecenter Phase 1/2 clinical trials evaluating REQORSA in combined with Tagrisso®? ("osimertinib") in patients with late-stageNSCLC with activating epider mal growth factor receptor mutations whose disease advanced after treatment with Tagrisso; The Acclaim-2 clinical trials, whose patient population received FDA fast Track Designation, is an Open-label, multi-center phase 1/2 clinical trial evaluatingREQORSA in combination with Keytruda®? (pembrolizumab) in patients with late- stage NSCLC whose disease progressed after treatment with Keytruda.

The upcoming Acclaim-3 clinical trial is an open-label, multiple-center Ph ase 1/2 clinical trial evaluating ReQORSA in combination with Tecentriq®? (atezolizumab) as maintenance therapy in patients with extensive-stage SCLC who did not develop tumor progression after receiving Tecentriq and chemotherapy as an initial treatment. The FDA granted both Fast Track and Orphan Drug Designation for REQORSA in the Acclaim-3 patient population.

Each of Genprex's three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trial is expected to be completed in 2023.